Akebia Therapeutics (NASDAQ:AKBA) & Reviva Pharmaceuticals (NASDAQ:RVPH) Financial Comparison

Akebia Therapeutics (NASDAQ:AKBA) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Risk & Volatility

Akebia Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.

Profitability

This table compares Akebia Therapeutics and Reviva Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-27.07%	N/A	-20.57%
Reviva Pharmaceuticals	N/A	N/A	-252.53%

Insider & Institutional Ownership

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 4.1% of Akebia Therapeutics shares are held by company insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Akebia Therapeutics and Reviva Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	0	0	1	0	3.00
Reviva Pharmaceuticals	0	1	2	1	3.00

Akebia Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 267.65%. Reviva Pharmaceuticals has a consensus target price of $15.50, suggesting a potential upside of 1,213.56%. Given Reviva Pharmaceuticals’ higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Akebia Therapeutics.

Earnings and Valuation

This table compares Akebia Therapeutics and Reviva Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$194.62 million	2.29	-$51.92 million	($0.23)	-8.87
Reviva Pharmaceuticals	N/A	N/A	-$39.26 million	($1.11)	-1.06

Reviva Pharmaceuticals has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Reviva Pharmaceuticals beats Akebia Therapeutics on 8 of the 12 factors compared between the two stocks.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.